Abstract: 【Abstract】 Currently, β-blockers are the first-line drugs for the treatment of infantile hemangioma, mainly including oral propranolol and topical timolol/carteolol eye drops. The selection and administration of β-blockers are mainly determined by factors such as children′s age, as well as tumor site, type, classification and size. This consensus summarizes indications and contraindications of oral propranolol, timing for initial therapy, start dose, start dose, course of treatment, indications for withdrawal, cautions during treatment, monitoring and management of adverse reactions, as well as therapeutic dose and course for special populations. The indications and specific administration methods of topical β-blockers are also described. It is hoped that this consensus provides a reference for dermatologists and relevant professional clinicians in proper application of β-blockers in the treatment of infantile hemangioma.

Key words: Hemangioma, Infant, Adrenergic beta-antagonists, Propranolol, Timolol, Carteolol, Expert consensus